Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify  CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Grifols S.A.

Grifols SA ( ($GRFS) ) has issued an update. On November 4, 2025, Grifols reported its third-quarter financial results, highlighting a 9.1% year-ov...

Market Cap	$5.91B	P/E Ratio	8.57
52W High	$11.14	52W Low	$6.19
Div Yield	17.3%	Payout Ratio	N/A
EPS Growth 3Y	0.0%	52W Position	44.6%
Overall Score	46	Value Score	75
Quality Score	--	Technical Score	18

EPS Current Est	$0.98	EPS Next Est	$1.3
EPS Growth Est	+32.7%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GRFS	$8.40	-0.36%	280.48K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GRFS	$8.40	-0.4%	280.48K
3
4
5
6

GRFS

GRFS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Grifols S.A. Data in Excel

Get Grifols S.A. Data in Excel